DelveInsight's "CARVYKTI Market Size, Forecast, and Market Insight Report" highlights the details around CARVYKTI, a ...

While we've known that a healthy diet reduces the overall chance of getting cancer, there's now evidence that one eating plan ...

The following is a summary of “Safety and activity of talquetamab in patients with relapsed or refractory multiple myeloma ...

As a BCMA-targeting CAR T-cell therapy, CARVYKTI addresses a high unmet need in relapsed or refractory multiple myeloma patients. With promising clinical efficacy, durable responses, and growing ...

Panelists discuss how ciltacabtagene autoleucel (cilta-cel) demonstrates superior outcomes compared to real-world physician’s ...

Panelists discuss how patients and caregivers considering late-line multiple myeloma therapies must navigate practical ...

The FDA has accepted the resubmitted BLA for linvoseltamab for patients with relapsed/refractory multiple myeloma.

New research suggests that a larger waist circumference is a bigger risk factor than body mass index (BMI) for ...

The company said that ZAMTO Cell is designed to target both CD19 and CD20, which could improve treatment efficacy.

This approval augments Biocon Pharma's complex injectables portfolio and reinforces its footprint in the US pharma market.

Body size and excess weight, conventionally assessed using body mass index (BMI), are well-established risk factors for many ...